SCM
KYTX icon

Superstring Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Superstring Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-142,542
Closed -$438K – 51
2025
Q2 		$438K Sell
142,542
-48,745
-25% -$121K 0.52% 32
2025
Q1 		$369K Buy
191,287
+9,110
+5% +$26.9K 0.44% 29
2024
Q4 		$681K Buy
+182,177
New +$873K 0.59% 30

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Superstring Capital Management's KYTX Position: Q3 2025 in Review

Superstring Capital Management sold out of Kyverna Therapeutics (KYTX) in Q3 2025, closing a stake of 142,542 shares — an estimated $438K sold.

Superstring Capital Management first reported a position in KYTX in Q4 2024 and held it in 3 quarters. The position peaked at $681K in Q4 2024. 75 funds tracked by Wall St. Rank hold KYTX as of Q3 2025.

  • Superstring Capital Management reported no remaining Kyverna Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Superstring Capital Management sold 142,542 Kyverna Therapeutics shares in Q3 2025, an estimated $438K.
  • Superstring Capital Management first reported a position in Kyverna Therapeutics in Q4 2024 and held it in 3 quarters.
  • Superstring Capital Management's Kyverna Therapeutics position peaked at $681K in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2025.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.